The JGL Scientific Advisory Board (SAB) was established today as an independent and international body that brings together leading national and foreign experts, which will strengthen the scientific profile of the company’s research and development projects.
The SAB consists of ten internationally renowned experts with extensive practical, regulatory, clinical and industrial experience in the fields of pharmacology, preclinical, clinical and regulatory phases of drug development, pharmaceutical product design, and drug delivery systems and technologies.
– We want to position JGL as an innovator in the development of advanced differentiated products within our three strategic therapeutic areas – flu and colds, ophthalmology and dermatology. Along with the implementation of the INTEGRA 2020 project, which will consolidate and strengthen our research, development and production capabilities, the establishment of the SAB is another step forward in the development of innovative products that make up our science and innovation ecosystem. The goal of this body is to cooperate with the JGL team and steer existing efforts and develop new ideas for the company’s production and technology portfolio with sound scientific reasoning – says Mislav Vučić, CEO of JGL, adding that he is extremely proud of leading scientists and talent coming together at the SAB’s first meeting held today in Rijeka. Through synergy, they are able to network and share relevant, science-based knowledge and ideas, and lay the groundwork for increasing the company’s competitiveness.
The JGL Scientific Advisory Board is coordinated by Zdravka Knežević, PhD, Head of Scientific and Expert Operations, who has participated in a number of similar global projects. Knežević, who joined the company’s ambitious team earlier this year, has over 30 years of experience in research and development, registration, and clinical and medical affairs.
– I am delighted to be able to share the knowledge and experience I gained from international companies at JGL, as well as to cooperate with a great team of scientists from Europe, United Kingdom, Russia, Ukraine, Turkey and other global markets within the SAB. I believe that this marks significant progress for JGL and our teams, as well as for Croatia as a whole, because we will be able to develop new products for the benefit of our patients and meet the treatment needs specific to modern life, with science at the forefront of our efforts, says Knežević.
Members of JGL’s Scientific Advisory Board include: Jag Ahluwalia, PhD, a leader with over 35 years of experience in regulatory affairs and quality, Andreas Bilstein, PhD, an experienced scientist, consultant and Managing Director of Ursatec, Prof. Henning H. Blume, PhD, a world-renowned expert in the wide field of biopharmaceuticals, Prof. Vasil Ivanovič Popovič, PhD, an esteemed ENT surgeon, paediatric otorhinolaryngologist and ENT oncologist from Ukraine, Sonja Jandroković, PhD, Chief Physician and Head of the Day Hospital and Day Surgery Department of the Clinic for Eye Diseases at the University Hospital Centre Zagreb, Prof. Stipan Jonjić, PhD, full professor and Head of the Department of Histology and Embryology and Head of the Centre for Proteomics at the Faculty of Medicine of the University of Rijeka, Prof. Jasmina Lovrić, PhD, Dean of the Faculty of Pharmacy and Biochemistry, Prof. Marina A. Mokronosova, PhD, Head of the Department of Allergology at the prestigious I. I. Mechnikov Clinical Hospital in Russia, Prof. Özgen Özer, PhD, Head of the Department of Pharmaceutical Technology at the Faculty of Pharmacy of Ege University in Izmir, and Prof. Vladimir Trkulja, PhD, full professor of pharmacology at the School of Medicine of the University of Zagreb.